Cargando…

CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors

BACKGROUND: Expression of killer cell lectin-like receptor B1 (KLRB1), the gene encoding the cell surface molecule CD161, is associated with favorable prognosis in many cancers. CD161 is expressed by several lymphocyte populations, but its role and regulation on tumor-specific CD4+ T cells is unknow...

Descripción completa

Detalles Bibliográficos
Autores principales: Duurland, Chantal L, Santegoets, Saskia J, Abdulrahman, Ziena, Loof, Nikki M, Sturm, Gregor, Wesselink, Tom H, Arens, Ramon, Boekestijn, Sanne, Ehsan, Ilina, van Poelgeest, Mariette I E, Finotello, Francesca, Hackl, Hubert, Trajanoski, Zlatko, ten Dijke, Peter, Braud, Veronique M, Welters, Marij J P, van der Burg, Sjoerd H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765066/
https://www.ncbi.nlm.nih.gov/pubmed/35039463
http://dx.doi.org/10.1136/jitc-2021-003995
_version_ 1784634286217887744
author Duurland, Chantal L
Santegoets, Saskia J
Abdulrahman, Ziena
Loof, Nikki M
Sturm, Gregor
Wesselink, Tom H
Arens, Ramon
Boekestijn, Sanne
Ehsan, Ilina
van Poelgeest, Mariette I E
Finotello, Francesca
Hackl, Hubert
Trajanoski, Zlatko
ten Dijke, Peter
Braud, Veronique M
Welters, Marij J P
van der Burg, Sjoerd H
author_facet Duurland, Chantal L
Santegoets, Saskia J
Abdulrahman, Ziena
Loof, Nikki M
Sturm, Gregor
Wesselink, Tom H
Arens, Ramon
Boekestijn, Sanne
Ehsan, Ilina
van Poelgeest, Mariette I E
Finotello, Francesca
Hackl, Hubert
Trajanoski, Zlatko
ten Dijke, Peter
Braud, Veronique M
Welters, Marij J P
van der Burg, Sjoerd H
author_sort Duurland, Chantal L
collection PubMed
description BACKGROUND: Expression of killer cell lectin-like receptor B1 (KLRB1), the gene encoding the cell surface molecule CD161, is associated with favorable prognosis in many cancers. CD161 is expressed by several lymphocyte populations, but its role and regulation on tumor-specific CD4+ T cells is unknown. METHODS: We examined the clinical impact of CD4+CD161+ T cells in human papillomavirus (HPV)16+ oropharyngeal squamous cell carcinoma (OPSCC), analyzed their contribution in a cohort of therapeutically vaccinated patients and used HPV16-specific CD4+CD161+ tumor-infiltrating lymphocytes and T cell clones for in-depth mechanistic studies. RESULTS: Central and effector memory CD4+ T cells express CD161, but only CD4+CD161+ effector memory T cells (Tem) are associated with improved survival in OPSCC. Therapeutic vaccination activates and expands type 1 cytokine-producing CD4+CD161+ effector T cells. The expression of CD161 is dynamic and follows a pattern opposite of the checkpoint molecules PD1 and CD39. CD161 did not function as an immune checkpoint molecule as demonstrated using multiple experimental approaches using antibodies to block CD161 and gene editing to knockout CD161 expression. Single-cell transcriptomics revealed KLRB1 expression in many T cell clusters suggesting differences in their activation. Indeed, CD4+CD161+ effector cells specifically expressed the transcriptional transactivator SOX4, known to enhance T cell receptor (TCR) signaling via CD3ε. Consistent with this observation, CD4+CD161+ cells respond more vigorously to limiting amounts of cognate antigen in presence of interleukin (IL)-12 and IL-18 compared to their CD161- counterparts. The expression of CD161/KLRB1 and SOX4 was downregulated upon TCR stimulation and this effect was boosted by transforming growth factor (TGF)β1. CONCLUSION: High levels of CD4+CD161+ Tem are associated with improved survival and our data show that CD161 is dynamically regulated by cell intrinsic and extrinsic factors. CD161 expressing CD4+ T cells rapidly respond to suboptimal antigen stimulation suggesting that CD161, similar to SOX4, is involved in the amplification of TCR signals in CD4+ T cells.
format Online
Article
Text
id pubmed-8765066
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-87650662022-02-08 CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors Duurland, Chantal L Santegoets, Saskia J Abdulrahman, Ziena Loof, Nikki M Sturm, Gregor Wesselink, Tom H Arens, Ramon Boekestijn, Sanne Ehsan, Ilina van Poelgeest, Mariette I E Finotello, Francesca Hackl, Hubert Trajanoski, Zlatko ten Dijke, Peter Braud, Veronique M Welters, Marij J P van der Burg, Sjoerd H J Immunother Cancer Basic Tumor Immunology BACKGROUND: Expression of killer cell lectin-like receptor B1 (KLRB1), the gene encoding the cell surface molecule CD161, is associated with favorable prognosis in many cancers. CD161 is expressed by several lymphocyte populations, but its role and regulation on tumor-specific CD4+ T cells is unknown. METHODS: We examined the clinical impact of CD4+CD161+ T cells in human papillomavirus (HPV)16+ oropharyngeal squamous cell carcinoma (OPSCC), analyzed their contribution in a cohort of therapeutically vaccinated patients and used HPV16-specific CD4+CD161+ tumor-infiltrating lymphocytes and T cell clones for in-depth mechanistic studies. RESULTS: Central and effector memory CD4+ T cells express CD161, but only CD4+CD161+ effector memory T cells (Tem) are associated with improved survival in OPSCC. Therapeutic vaccination activates and expands type 1 cytokine-producing CD4+CD161+ effector T cells. The expression of CD161 is dynamic and follows a pattern opposite of the checkpoint molecules PD1 and CD39. CD161 did not function as an immune checkpoint molecule as demonstrated using multiple experimental approaches using antibodies to block CD161 and gene editing to knockout CD161 expression. Single-cell transcriptomics revealed KLRB1 expression in many T cell clusters suggesting differences in their activation. Indeed, CD4+CD161+ effector cells specifically expressed the transcriptional transactivator SOX4, known to enhance T cell receptor (TCR) signaling via CD3ε. Consistent with this observation, CD4+CD161+ cells respond more vigorously to limiting amounts of cognate antigen in presence of interleukin (IL)-12 and IL-18 compared to their CD161- counterparts. The expression of CD161/KLRB1 and SOX4 was downregulated upon TCR stimulation and this effect was boosted by transforming growth factor (TGF)β1. CONCLUSION: High levels of CD4+CD161+ Tem are associated with improved survival and our data show that CD161 is dynamically regulated by cell intrinsic and extrinsic factors. CD161 expressing CD4+ T cells rapidly respond to suboptimal antigen stimulation suggesting that CD161, similar to SOX4, is involved in the amplification of TCR signals in CD4+ T cells. BMJ Publishing Group 2022-01-17 /pmc/articles/PMC8765066/ /pubmed/35039463 http://dx.doi.org/10.1136/jitc-2021-003995 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.
spellingShingle Basic Tumor Immunology
Duurland, Chantal L
Santegoets, Saskia J
Abdulrahman, Ziena
Loof, Nikki M
Sturm, Gregor
Wesselink, Tom H
Arens, Ramon
Boekestijn, Sanne
Ehsan, Ilina
van Poelgeest, Mariette I E
Finotello, Francesca
Hackl, Hubert
Trajanoski, Zlatko
ten Dijke, Peter
Braud, Veronique M
Welters, Marij J P
van der Burg, Sjoerd H
CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors
title CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors
title_full CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors
title_fullStr CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors
title_full_unstemmed CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors
title_short CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors
title_sort cd161 expression and regulation defines rapidly responding effector cd4+ t cells associated with improved survival in hpv16-associated tumors
topic Basic Tumor Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765066/
https://www.ncbi.nlm.nih.gov/pubmed/35039463
http://dx.doi.org/10.1136/jitc-2021-003995
work_keys_str_mv AT duurlandchantall cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors
AT santegoetssaskiaj cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors
AT abdulrahmanziena cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors
AT loofnikkim cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors
AT sturmgregor cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors
AT wesselinktomh cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors
AT arensramon cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors
AT boekestijnsanne cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors
AT ehsanilina cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors
AT vanpoelgeestmarietteie cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors
AT finotellofrancesca cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors
AT hacklhubert cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors
AT trajanoskizlatko cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors
AT tendijkepeter cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors
AT braudveroniquem cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors
AT weltersmarijjp cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors
AT vanderburgsjoerdh cd161expressionandregulationdefinesrapidlyrespondingeffectorcd4tcellsassociatedwithimprovedsurvivalinhpv16associatedtumors